// App-Quantinova.ai

: Clinical Intervention Using NGS-Based Kinase Domain Mutation Testing in CML Patients

Researchers

Presenter

  • Aytug Kizilors

Principal Investigators

  • Patrick Harrington

  • Sophie Jackson

  • Nicholas Lea

  • Joel Newman

  • Richard Gale

  • Sandra Hassan

  • Evangelia Dimitriadou

  • Elena Cris

  • Luke Ficinski

  • Isabel Sa

  • Anita Arasaretnam

  • Vijayavalli Dhanapal

  • Timothy Corbett

  • Robin M. Ireland

  • Antonio Pagliuca

  • Ghulam J. Mufti

  • Hugues De Lavallade

Medical Centers

  • Haematology, Kings College London, LONDON, United Kingdom

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • Kings College London, London, UK

  • Kings College Hospital NHS Foundation Trust,London,Reino Unido

  • East Sussex Healthcare NHS Trust, Haematology, Eastbourne District General Hospital, Eastbourne, United Kingdom

  • The Tunbridge Wells Hospital At Pembury, Tunbridge Wells, GBR

  • Haematology, Queens Hospital, Romford, United Kingdom

  • Haematology department, Maidstone Hospital, Maidstone, United Kingdom

  • Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy, Novara, Italy

  • Brighton and Sussex University Hospitals NHS Trust, Sussex Cancer Centre, Brighton, United Kingdom

  • Medway Maritime Hospital, Gillingham, United Kingdom

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • Kings College London, London, United Kingdom

  • King's College London, Molecular Haematology, Division of Cancer Studies, London, United Kingdom

  • Department of Haematological Medicine, King's College London, London, United Kingdom

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • Gastroenterology Department, Kings College Hospital, London, United Kingdom

Locations

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Nilotinib

  • Ponatinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved